Menu Search
Equities

Nxera Pharma Co Ltd

JSS:BER

Nxera Pharma Co Ltd

Actions
  • Price (EUR)7.00
  • Today's Change0.150 / 2.19%
  • Shares traded--
  • 1 Year change-27.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

  • Revenue in JPY (TTM)29.28bn
  • Net income in JPY-3.71bn
  • Incorporated1990
  • Employees350.00
  • Location
    Nxera Pharma Co LtdMidtown East, 9-7-2, AkasakaMINATO-KU 107-0052JapanJPN
  • Phone+81 352103290
  • Fax+81 352103291
  • Websitehttps://www.nxera.life/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.